Plus Therapeutics (PSTV) said Friday that its experimental drug, rhenium obisbemeda, demonstrated a median overall survival of 11 months in an early-stage study, outperforming the standard of care of 8 months for recurrent glioblastoma, a type of brain tumor.
The clinical-stage company said that the study showed no dose-limiting toxicity, and that the majority of adverse events were unrelated to the treatment.
Plus Therapeutics said that, based on these results, it is currently enrolling patients in a mid-stage trial at medical centers.
Shares of the company climbed as much as 40% in recent premarket activity on Friday.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。